Related references
Note: Only part of the references are listed.Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Stefan Leucht et al.
LANCET (2012)
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)
Lamiae Grimaldi-Bensouda et al.
SCHIZOPHRENIA RESEARCH (2012)
A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
Jari Tiihonen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Extended Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Gary Remington et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Robert A. Rosenheck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The place of observational studies in assessing the effectiveness of depot antipsychotics
Peter M. Haddad et al.
SCHIZOPHRENIA RESEARCH (2011)
Oral versus depot antipsychotic drugs for schizophrenia A critical systematic review and meta-analysis of randomised long-term trials
Claudia Leucht et al.
SCHIZOPHRENIA RESEARCH (2011)
Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
Tim Lambert et al.
ANNALS OF GENERAL PSYCHIATRY (2011)
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
John M. Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Wolfgang Gaebel et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht et al.
LANCET (2009)
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
S. Leucht et al.
MOLECULAR PSYCHIATRY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Less is more: Antipsychotic drug effects are greater with transient rather than continuous delivery
Anne-Noel Samaha et al.
BIOLOGICAL PSYCHIATRY (2008)
Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study
Neeltje E. M. van Haren et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Relationships among subjective and objective measures of adherence to oral antipsychotic medications
Dawn I. Velligan et al.
PSYCHIATRIC SERVICES (2007)
Equivalent switching dose from oral risperidone to risperidone long-acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study
Ya Mei Bai et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
Nicholas A. Keks et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time
Anne-Noel Samaha et al.
JOURNAL OF NEUROSCIENCE (2007)
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder:: observational follow-up study
Jari Tiihonen et al.
BRITISH MEDICAL JOURNAL (2006)
Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence
C Arango et al.
EUROPEAN PSYCHIATRY (2006)
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder
ID Glick et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials
S Leucht et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Chlorpromazine equivalent doses for the newer atypical antipsychotics
SW Woods
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Antipsychotic medication adherence: Is there a difference between typical and atypical agents?
CR Dolder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
JA Lieberman et al.
BIOLOGICAL PSYCHIATRY (2001)
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans:: a clinical PET study
S Silvestri et al.
PSYCHOPHARMACOLOGY (2000)
Share Paper
